Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 17/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.74 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.74 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fenarimol SCHEMBL42209 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP3A5 | |
| Fenarimol SCHEMBL30412723 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP3A5 | |
| Fenarimol SCHEMBL8360554 | 1.00 | CYP19A1 (1.00) | CYP19A1CYP3A4CYP3A5 | |
| Fenarimol SCHEMBL8300815 | 0.98 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP3A5 | |
| Fenarimol SCHEMBL7190386 | 0.98 | CYP19A1 (0.97) | CYP19A1CYP3A4CYP3A5 | |
| Fenarimol SCHEMBL4292949 | 0.93 | CYP19A1 (0.86) | CYP19A1CYP3A4CYP3A5 | |
| Fenarimol SCHEMBL3821324 | 0.93 | CYP19A1 (0.86) | CYP19A1CYP3A4CYP3A5 | |
| Fenarimol SCHEMBL8408558 | 0.92 | CYP3A4 (0.90) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL27282170 | 0.90 | CYP19A1 (0.82) | CYP19A1CYP3A4CYP3A5 | |
| SCHEMBL6521386 | 0.89 | CYP19A1 (0.79) | CYP19A1CYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6767923-B2 | Benzhydryl derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2004-07-27 | — | — | US | disclosed |
| EP-1308433-B1 | Benzhydryl derivatives | BASF AG (DE) | 2004-04-28 | — | — | EP | disclosed |
| US-20030207938-A1 | Such as 5-bromo-6,6'-dimethyl-2,2',3',4'-tetramethoxybenz-hydryl alcohol for controlling harmful phytopathogenic fungi | BASF AKTIENGESELLSCHAFT (DE) | 2003-11-06 | — | — | US | disclosed |
| EP-1308433-A1 | Benzhydryl derivatives | BASF AKTIENGESELLSCHAFT (DE) | 2003-05-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030207938-A1 | Such as 5-bromo-6,6'-dimethyl-2,2',3',4'-tetramethoxybenz-hydryl alcohol for controlling harmful phytopathogenic fungi | CBR1, CBR3, ADH5 | CYP19A1 4138/4885CYP3A4 699/4885CYP3A5 825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.